Tossetta Giovanni, Fantone Sonia, Gesuita Rosaria, Goteri Gaia, Senzacqua Martina, Marcheggiani Fabio, Tiano Luca, Marzioni Daniela, Mazzucchelli Roberta
Department of Experimental and Clinical Medicine, Università Politecnica delle Marche, 60126 Ancona, Italy.
Centre of Epidemiology, Biostatistics and Medical Information Technology, Università Politecnica delle Marche, 60126 Ancona, Italy.
Cancers (Basel). 2022 Nov 30;14(23):5917. doi: 10.3390/cancers14235917.
Prostate cancer (PCa) remains the most common diagnosed tumor and is the second-leading cause of cancer-related death in men. If the cancer is organ-confined it can be treated by various ablative therapies such as RP (radical prostatectomy), RT (radiation therapy), brachytherapy, cryosurgery or HIFU (High-Intensity Focused Ultrasound). However, advanced or metastatic PCa treatment requires systemic therapy involving androgen deprivation, but such patients typically progress to refractory disease designated as castration-resistant prostate cancer (CRPC). Interleukin-6 (IL-6) has been established as a driver of prostate carcinogenesis and tumor progression while less is known about the role of ciliary neurotrophic factor (CNTF), a member of the IL-6 cytokine family in prostate cancer. Moreover, MAPK/ERK, AKT/PI3K and Jak/STAT pathways that regulate proliferative, invasive and glucose-uptake processes in cancer progression are triggered by CNTF.
We investigate CNTF and its receptor CNTFRα expressions in human androgen-responsive and castration-resistant prostate cancer (CRPC) by immunohistochemistry. Moreover, we investigated the role of CNTF in proliferative, invasive processes as well as glucose uptake using two cell models mimicking the PCa (LNCaP cell line) and CRPC (22Rv1 cell line).
Our results showed that CNTF and CNTFRa were expressed in PCa and CRPC tissues and that CNTF has a pivotal role in prostate cancer environment remodeling and as a negative modulator of invasion processes of CRPC cell models.
前列腺癌(PCa)仍然是最常被诊断出的肿瘤,是男性癌症相关死亡的第二大原因。如果癌症局限于器官内,可以通过各种消融疗法进行治疗,如根治性前列腺切除术(RP)、放射治疗(RT)、近距离放射治疗、冷冻手术或高强度聚焦超声(HIFU)。然而,晚期或转移性PCa的治疗需要进行涉及雄激素剥夺的全身治疗,但这类患者通常会进展为难治性疾病,即去势抵抗性前列腺癌(CRPC)。白细胞介素-6(IL-6)已被确认为前列腺癌发生和肿瘤进展的驱动因素,而关于睫状神经营养因子(CNTF),即IL-6细胞因子家族的一员在前列腺癌中的作用,人们了解较少。此外,调节癌症进展中增殖、侵袭和葡萄糖摄取过程的丝裂原活化蛋白激酶/细胞外信号调节激酶(MAPK/ERK)、蛋白激酶B/磷脂酰肌醇-3激酶(AKT/PI3K)和酪氨酸激酶/信号转导子和转录激活子(Jak/STAT)途径会被CNTF激活。
我们通过免疫组织化学研究了CNTF及其受体CNTFRα在人雄激素反应性和去势抵抗性前列腺癌(CRPC)中的表达。此外,我们使用两种模拟PCa(LNCaP细胞系)和CRPC(22Rv1细胞系)的细胞模型,研究了CNTF在增殖、侵袭过程以及葡萄糖摄取中的作用。
我们的结果表明,CNTF和CNTFRα在PCa和CRPC组织中均有表达,并且CNTF在前列腺癌环境重塑中起关键作用,是CRPC细胞模型侵袭过程的负调节因子。